5 July 2013
 
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces an agreement to acquire certain assets related to the distribution of its orthopaedic reconstruction, trauma and sports medicine products in Turkey, currently conducted through Plato Grup.
 
The acquisition is in line with Smith & Nephew’s strategic priority to expand in emerging markets.  
 
Olivier Bohuon, Chief Executive Officer of Smith & Nephew, commented:
 
“We are pleased to be able to make this investment, delivering on our strategy to develop sustainable businesses in markets with good long-term growth profiles. Turkey is a fast-growing market with substantial opportunity and Plato is one of the leading businesses in our segment. With this acquisition we will be building upon a proven commercial platform, good reputation and strong relationships. We will be closer to our customers and able to target new opportunities more actively.”
 
It is anticipated that all Plato employees will join Smith & Nephew, including management and the sales team. Plato has worked for Smith & Nephew since it was founded in 1995.
 
The acquisition, which is being made through the local subsidiary of Smith & Nephew, is expected to close in the second half of 2013 subject to the satisfaction of certain customary conditions. The terms have not been disclosed.

-  ends -

Enquiries

Investors 
Phil Cowdy  +44 (0) 20 7401 7646
Smith & Nephew 
 
Media 
Charles Reynolds  +44 (0) 20 7401 7646
Smith & Nephew 
 
Andrew Mitchell / Justine McIlroy +44 (0) 20 7404 5959
Brunswick 

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has around 10,500 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).